Today: May 27, 2016, 6:41 am

Global HIV market: Latest market research analysed
HIV Partnering 2007-2013 - a new market research report on 2014-03-13 12:30:05
The HIV Partnering 2007-2013 provides understanding and access to the HIV partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of HIV partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors HIV technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 260 links to online copies of actual HIV deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of HIV partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in HIV partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading HIV deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of HIV partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of HIV technologies and products.

Report Scope

HIV Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to HIV trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in HIV dealmaking in the biopharma industry since 2007
Access to summary headline, upfront, milestone and royalty data
The leading HIV deals by value since 2007

In HIV Partnering 2007-2013, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

HIV Partnering 2007-2013 provides the reader with the following key benefits:

In-depth understanding of HIV deal trends since 2007
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 260 actual HIV deals entered into by the worlds biopharma companies since 2007
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in HIV partnering

2.1. Introduction
2.2. HIV partnering over the years
2.3. Bigpharma HIV dealmaking activity
2.4. HIV partnering by deal type
2.5. HIV partnering industry sector
2.6. HIV partnering by stage of development
2.7. HIV partnering by technology type
2.8. Disclosed financial deal terms for HIV partnering
2.8.1 HIV headline values
2.8.2 HIV upfront payments
2.8.3 HIV milestone payments
2.8.4 HIV royalty rates
Chapter 3 – Leading HIV deals

3.1. Introduction
3.2. Top HIV deals by value
3.3. Top HIV deals involving bigpharma
Chapter 4 – Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Collaborative R&D
Contract service
Equity purchase
Joint venture
Spin out
4.4. By industry sector
Drug delivery
Medical device
Generic pharma
Research tools
Specialty pharma
4.5. By stage of development
Phase I
Phase II
Phase III
4.6. By technology type
Animal models
Biological compounds
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Discovery tools
DNA probes
Drug delivery
Enabling technology
Gene therapy
Industrial chemicals
In vitro models
Monoclonal antibodies
Personalised medicine
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Small molecules
Stem cells
Chapter 5 – Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures

Figure 1: HIV partnering since 2007
Figure 2: Bigpharma – top 50 – HIV deals 2007 to 2011
Figure 3: Bigpharma HIV deal frequency – 2007 to 2011
Figure 4: HIV partnering by deal type since 2007
Figure 5: HIV partnering by industry sector since 2007
Figure 6: HIV partnering by stage of development since 2007
Figure 7: HIV partnering by technology type since 2007
Figure 8: HIV deals with a headline value
Figure 9: HIV deals with upfront payment values
Figure 10: HIV deals with milestone payments
Figure 11: HIV deals with royalty rates, %
Figure 12: Top HIV deals by value since 2007
Figure 13: Top HIV deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
$1,695: single-user
$2,595: multi-user
$5,095: single site license
$8,475: global site license
An annual subscription to quarterly updates can be purchased for a small additional fee; ensuring you are kept up-to-date with the very latest HIV partnering deals. Quarterly updates available from $847.50.

A full explanation of license type definitions can be found here.

An additional $500 per copy will be added for full print and CD-ROM requests.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 1207 Words
Related Articles
More From Finance
New Frontier Portfolios Top Morningstar Rankings
Boston, April 14, 2016—New Frontier’s global strategic portfolios topped the Global Balanced Strategic category of the latest [..]
Finding an Excellent Tax Lawyer with the [..]
Sound Advice about Finding an Excellent Attorney When an individual requires legal representation, whether for an IRS tax debt [..]
First Gothenburg Bancshares to acquire Nebanco, Inc.
Denver, CO: March 24, 2016 – First Gothenburg Bancshares, Inc., the holding company for First State Bank, Gothenburg, Nebraska [..]
With Bad Credit It Is Still Possible [..]
What to Expect When Seeking a Bad Credit Home Loan Refinance Okay, so not everyone has great – or even [..]
Credit-Yogi Professionals Describe How to Get Out [..]
Who doesn’t want to save money while getting rid of debt? Most folks would jump at the chance to do [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.